Anixa Biosciences (NASDAQ:ANIX) Announces Quarterly Earnings Results

Anixa Biosciences (NASDAQ:ANIX) released its quarterly earnings data on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03, FiscalAI reports.

Anixa Biosciences Stock Performance

Shares of NASDAQ:ANIX opened at $2.50 on Friday. The company’s fifty day moving average is $2.78 and its two-hundred day moving average is $3.10. The stock has a market capitalization of $83.83 million, a price-to-earnings ratio of -8.06 and a beta of 0.59. Anixa Biosciences has a 1-year low of $2.32 and a 1-year high of $5.46.

Hedge Funds Weigh In On Anixa Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of ANIX. NewEdge Advisors LLC acquired a new position in Anixa Biosciences during the 2nd quarter valued at about $33,000. Cetera Investment Advisers acquired a new stake in Anixa Biosciences in the fourth quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. lifted its position in Anixa Biosciences by 2,000.0% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after purchasing an additional 10,000 shares during the period. Benjamin Edwards Inc. acquired a new stake in Anixa Biosciences in the second quarter worth approximately $37,000. Finally, Millennium Management LLC acquired a new stake in Anixa Biosciences in the fourth quarter worth approximately $38,000. Institutional investors own 29.13% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ANIX shares. D. Boral Capital reiterated a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, April 8th. Wall Street Zen downgraded shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Anixa Biosciences has a consensus rating of “Hold” and a consensus target price of $8.50.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.